Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.

This is a source-metadata record last found in a complete check on Sep 28, 2026. It is not a Pependium assessment of safety or effectiveness. Check the original sources for current details, corrections and full methods.

Source status: This saved record has not yet had a scheduled exact-ID status check. Check its original source links.

Study metadata

Study type: Original study
Study category (metadata hint): Animal
Source date: Published: 2022-09-12
Authors: Geisler CE, Antonellis MP, Trumbauer W, Martin JA, Coskun T, Samms RJ, Hayes MR.
Journal or registry: Diabetes, obesity & metabolism
Registry study design: Not reported
Registry enrollment: Not reported
Funding agencies: National Institute of Diabetes and Digestive and Kidney Diseases; Eli Lilly and Company; NIDDK NIH HHS
Identifiers: DOI: 10.1111/dom.14843 · PMID: 36054312 · PMCID: PMC10362946
First found: Sep 28, 2026
Last found: Sep 28, 2026

Original sources

View at Europe PMC ↗View at PubMed ↗